Fundraising Fox

OrsoBio

Menlo Park, US · Founded 2020 · Delaware corporation · 3 known investors

Biotech

Founders & leadership

MS
Mani SubramanianExecutive
GG
Gangadhara GanapatiExecutive

Board

MY
Matthew YounginBoard directorManaging Director at Longitude Capital
SA
Srinivas AkkarajuBoard director
CF
Cory FreedlandBoard director
EF
Edward FlemingBoard director
ER
Evan RachlinBoard director
MM
Muzammil MansuriBoard director

Investors · 3

Longitude CapitalMenlo Park · $10M – $30M
Samsara BioCapitalPalo Alto
Ascenta CapitalreportedWilmington

Reported raises · per SEC filings

Form D private placements

$124.6M disclosed across 2 rounds · 2023–2024

▶$40MraisedAug 2024 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Matthew YoungDirector
  • Mani SubramanianExecutive Officer, Director
  • Srinivas AkkarajuDirector
  • Cory FreedlandDirector
  • Edward FlemingDirector
  • Evan RachlinDirector
  • Muzammil MansuriDirector
  • Gangadhara GanapatiExecutive Officer, Director
Offering amount
$67M
Amount sold
$40M
First sale
Aug 2024
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$84.6MraisedNov 2023 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Gangadhara GanapatiExecutive Officer, Director
  • Mani SubramanianExecutive Officer, Director
  • Cory FreedlandDirector
  • Muzammil MansuriDirector
  • Matthew YoungDirector
  • Edward FlemingDirector
  • Srinivas AkkarajuDirector
Offering amount
$84.6M
Amount sold
$84.6M
First sale
Oct 2023
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Bioworld51 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Bridgebio40 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.

Companies competing with OrsoBio for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

OrsoBio gains funds to develop obesity portfoliofinance.yahoo.com · Sep 2024Exclusive: Lilly-backed OrsoBio raises $67M for slate of obesity drugs as combinations take root - OrsoBioorsobio.com · Sep 2024OrsoBio Announces Oversubscribed $67 Million Series B Financing to Accelerate Mitochondrial Protonophore Portfolio Targeting Obesity and Associated Disorders - OrsoBioorsobio.com · Sep 2024Obesity drug startup raises $67M; Vor’s ‘shielded transplant’ shows promise | BioPharma Divebiopharmadive.com · Sep 2024OrsoBio: $60 Million Raised To Develop Treatments For Severe Metabolic Disorderspulse2.com · Dec 2023OrsoBio raises $60m to advance treatment for obesitypharmaceutical-business-review.com · Nov 2023

Frequently asked questions

Who are OrsoBio's investors?
OrsoBio's investors include Longitude Capital, Samsara BioCapital, Ascenta Capital.
How much funding has OrsoBio raised?
OrsoBio has disclosed $124.6M raised across 2 rounds.
Where is OrsoBio headquartered?
OrsoBio is headquartered in Menlo Park, US.